Anti-Rheumatic Drugs - Gambia

Gambia

The revenue in the Anti-Rheumatic Drugs market in Gambia is estimated to reach US$136.90k in 2024.
It is expected to demonstrate a compound annual growth rate (CAGR 2024-2029) of 0.75%, leading to a market volume of US$142.10k by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$34,700.00m in 2024.
Despite the high prevalence of rheumatic diseases in Gambia, the availability of affordable anti-rheumatic drugs remains a major challenge for patients.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Gambia has been showing some interesting trends in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and other related diseases prefer to use Anti-Rheumatic Drugs to treat their condition. This is due to the fact that these drugs help alleviate the symptoms associated with these diseases, such as joint pain, swelling, and stiffness.

Trends in the market: The Anti-Rheumatic Drugs market in Gambia has been growing steadily in recent years. This growth can be attributed to several factors, including an increase in the number of patients suffering from rheumatoid arthritis and related diseases, an increase in the availability of these drugs in the market, and an increase in the number of healthcare facilities offering treatment for these conditions.

Local special circumstances: One of the main challenges facing the Anti-Rheumatic Drugs market in Gambia is the lack of awareness about these drugs among the general public. This is due to a lack of education and information about these drugs, as well as a lack of access to healthcare facilities that offer treatment for these conditions.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Gambia is also influenced by several underlying macroeconomic factors. These include the overall economic growth of the country, the government's investment in healthcare infrastructure, and the availability of funding for research and development in the pharmaceutical industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.